Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synthetic bioconjugates

A conjugate and biological technology, applied in the direction of non-active ingredient medical preparations, active ingredient-containing medical preparations, drug combinations, etc.

Pending Publication Date: 2020-02-18
SYMIC HLDG (USA) INC
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It was also found that having branched peptides resulted in improved binding

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthetic bioconjugates
  • Synthetic bioconjugates
  • Synthetic bioconjugates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0253] Example 1. Synthesis of bioconjugates

[0254] Bioconjugates can be prepared according to the following scheme. Use an appropriate concentration of a chaotropic agent such as butanol, ethanol, guanidine chloride, lithium perchlorate, lithium acetate, magnesium chloride, phenol, propanol, sodium lauryl sulfate, thiourea, or urea (e.g. about 5M to about 10M urea), prepare a suitable reaction buffer (eg, 2-(N-morpholino)ethanesulfonic acid (MES)). The final pH was adjusted to pH about 4.5 to about 6 with 1 N HCl.

[0255] Hydrazide-functionalized peptides (eg, peptides 1-20 in Table 2) were dissolved in reaction buffer to 3 mg / mL. The peptide solution was prepared freshly prior to the coupling reaction. The corresponding biotinylated peptides were dissolved in reaction buffer to 3 mg / mL. Prepare the resulting biotinylated peptide solution freshly prior to the coupling reaction. Glycans (such as heparin (MW avg = 16 kDa)) was dissolved in reaction buffer to 20 mg / mL a...

Embodiment 2

[0265] Example 2. Collagen binding plate test

[0266] The following method was used to assess the binding affinity of the bioconjugates disclosed herein for collagen.

[0267] Collagen binding of the bioconjugate variants was compared by plate assay in which collagen was coated on 96-well plates. The collagen was coated on the high-binding plate with 50 μg / mL 0.02N acetic acid solution for 1 h at room temperature. Unbound collagen was washed with pH 7.4 IX PBS. Plates were then blocked in 1% milk in IX PBS for 1 hour at room temperature.

[0268] Bioconjugate variants containing biotinylated peptides were dissolved in 1% milk in 1X PBS pH 7.4 to a final concentration of 1 mg / mL. From this solution, 1OX serial dilutions were performed. Molecules were then incubated on blocked collagen-coated plates for 15 minutes at room temperature. Plates were then washed 3 times with 1X PBS containing 1% BSA and 0.2% Tween20.

[0269] Bound molecules were detected by streptavidin-HRP,...

Embodiment 3

[0282] Example 3. Platelet Aggregation

[0283] Type I fibrillar collagen was adsorbed onto Ibidi μ-slides by overnight incubation at 2–8 °C. Ibidi μ-slides were rinsed with phosphate buffered saline (PBS) and then blocked with 1% BSA in 1x PBS. 2mg / mL of compound 10 (such as Figure 12 B) and compound 1 (as Figure 12 Indicated in A) were applied to Ibidi μ-slides and allowed to incubate. After 1 hour, excess conjugate was washed away with 1x PBS. Freshly drawn human whole blood was prestained with Calcein AM (a live fluorescent cell marker). Blood was pumped through the channel using a syringe pump at a shear rate of 1000 s-1 for 10 min. Fluorescence microscopy was used to capture images of aggregated fluorescently labeled platelets as blood flowed across the Ibidi μ-slide. Figure 12 shows compound 10 (small Figure 12 B) Inhibition of platelet binding to type I fibrillar collagen.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

Provided herein are bioconjugates comprising a backbone and at least one branched or unbranched peptide having at least one collagen-binding unit covalently bonded thereto via a spacer and methods ofuse thereof.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 62 / 530,047, filed July 07, 2017, the disclosure of which is incorporated herein by reference in its entirety. technical field [0003] The present invention provides a bioconjugate comprising a backbone and at least one branched or unbranched peptide having at least one collagen binding unit covalently bound thereto by a spacer. Background technique [0004] In tissues, cells are surrounded by an extracellular matrix (ECM) comprising various macromolecules such as bioconjugates, collagen, hyaluronic acid, laminin, fibronectin, and the like. In mammals, bioconjugates are major components of the extracellular matrix where they form large complexes with other bioconjugates, hyaluronic acid, and fibrous matrix proteins such as collagen. As mammals age and in certain disease states, the extracellular matrix in certain par...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/61A61K47/64A61K31/715A61K31/727A61K31/728A61K31/737A61K38/00A61K38/08
CPCA61K38/00C07K14/00A61K47/61A61K47/65A61P9/00A61P1/16A61K47/64A61P43/00C07K14/001C07K7/08
Inventor 约翰·埃里克·帕代里茱莉娅·陈萨曼莎·萨哈
Owner SYMIC HLDG (USA) INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com